Global Diabetic Kidney Disease Market Report 2023: Forecast Market Size, Growth Rate And Key Drivers
6 Jun, 2023
The global diabetic kidney disease market size is expected to grow from $2.37 billion in 2022 to $2.51 billion in 2023 at a compound annual growth rate (CAGR) of 5.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global diabetic kidney disease market size is expected to reach $3.09 billion in 2027 at a CAGR of 5.4%.
Global Diabetic Kidney Disease Market Key Driver
The increased prevalence of chronic kidney disease is likely to boost the diabetic renal disease market forward. Chronic kidney disease (CKD) is a long-term disorder that causes the loss of kidney function over time, resulting in a variety of consequences such as high blood pressure, anaemia, and bone ailments. The treatment of chronic kidney disorders necessitates diagnostic and therapy options, which eventually fuels the growth of the diabetic kidney disease market.
Get a sample of the global diabetic kidney disease market reportGlobal Diabetic Kidney Disease Market Segments
The global diabetic kidney disease market is segmented:
1) By Type: Type 1 Diabetes, Type 2 Diabetes
2) By Treatment: Angiotensin Receptor Blockers (Arbs), Angiotensin-Converting Enzyme (Ace) Inhibitors, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Other Treatments
3) By End User: Hospitals, Homecare, Speciality Centres, Other End Users
4) By Geography: The regions covered in the diabetic kidney disease market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global diabetic kidney disease market.
Major Diabetic Kidney Disease Industry Players
AstraZeneca, Pfizer Inc., Novartis AG, Bayer AG, Sanofi Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Mylan NV, Aurobindo Pharma, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Reata Pharmaceuticals, Merck & Co.
Get the full global diabetic kidney disease market report
Diabetic Kidney Disease Market Overview
Diabetic kidney disease refers to a type of renal disease driven by complications of diabetes that occurs when high levels of blood sugar cause damage to the kidneys. The blood vessels in the kidneys can become affected by high blood glucose, which ultimately reduces their functionality.
Diabetic Kidney Disease Global Market Report 2023 provides data on the global diabetic kidney disease market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The diabetic kidney disease market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.